title: A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits.
abstract: Plasminogen activator inhibitor-1 (PAI-1), the major physiologic inhibitor of tissue-type plasminogen activator and urokinase, is abundantly expressed in atherosclerotic vascular wall. To determine the role of PAI-1 in vascular wall, we have used a novel inhibitor of PAI-1, (3E, 4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene) -pyrrolidine-2,5-dione (T-686). T-686 was given to human vascular endothelial cells in vitro and to rabbits subjected to high cholesterol diet and mechanical injury in vivo. T-686 attenuated the augmentation of PAI-1 antigen accumulation induced by transforming growth factor beta in conditioned medium from the human umbilical vein endothelial cells. In rabbits with aortic atherosclerosis induced by hypercholesterolemia and implantation of indwelling plastic tubing, oral administration of T-686 (30mg/kg body weight/day) for 8 weeks attenuated the increase in plasma PAI-1 activity induced by vascular injury without decreasing blood triglyceride and cholesterol. This was accompanied by the reduction in aortic PAI-1 mRNA expression and the inhibition of development of atherosclerosis lesions. Thus, T-686 not only decreased PAI-1 synthesis in vascular cells in vitro but also protected against the development of vascular lesions in vivo. This compound may be useful in defining the role of PAI-1 in atherothrombotic states.
authors.affiliation: Department of Medicine, University of Vermont, College of Medicine, Burlington 05405, USA.
authors.forename: B
authors.initials: B
authors.lastname: Vinogradsky
authors.forename: S P
authors.initials: SP
authors.lastname: Bell
authors.forename: J
authors.initials: J
authors.lastname: Woodcock-Mitchell
authors.forename: A
authors.initials: A
authors.lastname: Ohtani
authors.forename: S
authors.initials: S
authors.lastname: Fujii
mesh_terms: D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000378:metabolism*; D001597:Benzylidene Compounds / Q000494:pharmacology*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006937:Hypercholesterolemia / Q000378:metabolism; D008055:Lipids / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis* / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D011817:Rabbits; D013388:Succinimides / Q000494:pharmacology*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014471:Umbilical Veins / Q000166:cytology / Q000378:metabolism
chemical_list: D001597:Benzylidene Compounds; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D013388:Succinimides; D016212:Transforming Growth Factor beta; C104988:T 686; D010959:Tissue Plasminogen Activator